Editorial: Genomic discoveries and pharmaceutical development in urologic tumors.
作者信息
Meng Jialin, Yang Huan, Yin Lei
机构信息
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Institute of Urology and Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China.
出版信息
Front Pharmacol. 2024 Dec 9;15:1508979. doi: 10.3389/fphar.2024.1508979. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Genomic discoveries and pharmaceutical development in urologic tumors.社论：泌尿肿瘤的基因组学发现与药物研发
Front Pharmacol. 2024 Dec 9;15:1508979. doi: 10.3389/fphar.2024.1508979. eCollection 2024.
2
Nucleic acid-based tissue biomarkers of urologic malignancies.泌尿系统恶性肿瘤的基于核酸的组织生物标志物。
Crit Rev Clin Lab Sci. 2014 Aug;51(4):173-99. doi: 10.3109/10408363.2014.906130. Epub 2014 May 30.
3
Use of genomic markers to improve epidemiologic and clinical research in urology.利用基因组标志物提高泌尿科的流行病学和临床研究。
Curr Opin Urol. 2023 Nov 1;33(6):414-420. doi: 10.1097/MOU.0000000000001126. Epub 2023 Aug 29.
4
Strategies for targeted tumor assessment and elimination: the physician-scientist and the blossoming of molecular medicine in urologic oncology.靶向肿瘤评估与消除策略：医学科学家与泌尿肿瘤学中分子医学的蓬勃发展
Urol Oncol. 2006 Mar-Apr;24(2):117-8. doi: 10.1016/j.urolonc.2005.11.032.
5
Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes.用于改善肾癌、前列腺癌和膀胱癌健康差异结果的新兴基因组生物标志物。
Urol Oncol. 2022 Apr;40(4):126-132. doi: 10.1016/j.urolonc.2019.04.024. Epub 2019 Jun 23.
6
Identifying causal relationships between 35 blood and urine biomarkers and urologic cancers: MR-meta combined with Bayesian colocalization Mendelian randomization analysis.确定35种血液和尿液生物标志物与泌尿系统癌症之间的因果关系：磁共振元分析结合贝叶斯共定位孟德尔随机化分析
Discov Oncol. 2024 Nov 4;15(1):617. doi: 10.1007/s12672-024-01493-0.
7
8
Identification of molecular targets in urologic oncology.泌尿肿瘤学中分子靶点的鉴定
World J Urol. 2009 Feb;27(1):3-8. doi: 10.1007/s00345-008-0339-z. Epub 2008 Nov 12.
9
Molecular signatures in urologic tumors.泌尿肿瘤的分子特征。
Int J Mol Sci. 2013 Sep 6;14(9):18421-36. doi: 10.3390/ijms140918421.
10
Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases.通过药理学数据库中的非靶标药物结合相互作用对肿瘤药物进行计算再利用。
Clin Transl Med. 2024 Apr;14(4):e1657. doi: 10.1002/ctm2.1657.
本文引用的文献
1
FGFR Inhibition in Urothelial Carcinoma.成纤维细胞生长因子受体（FGFR）在尿路上皮癌中的抑制作用
Eur Urol. 2025 Feb;87(2):110-122. doi: 10.1016/j.eururo.2024.09.012. Epub 2024 Sep 30.
2
Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology.基础研究的临床意义：探索空间组学在泌尿肿瘤学中的变革潜力
Eur Urol. 2025 Jan;87(1):8-14. doi: 10.1016/j.eururo.2024.08.025. Epub 2024 Sep 2.
3
Cancer incidence and mortality in China, 2022.2022年中国癌症发病率与死亡率
J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. doi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.
4
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
5
Targeting the Androgen Signaling Axis in Prostate Cancer.靶向前列腺癌的雄激素信号通路。
J Clin Oncol. 2023 Sep 10;41(26):4267-4278. doi: 10.1200/JCO.23.00433. Epub 2023 Jul 10.
6
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review.联合免疫疗法在晚期肾细胞癌一线治疗中的新作用：综述。
JAMA Oncol. 2019 Mar 1;5(3):411-421. doi: 10.1001/jamaoncol.2018.4604.
7
Comprehensive molecular characterization of urothelial bladder carcinoma.尿路上皮膀胱癌的综合分子特征分析
Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29.
8
From the 19th to the 21st centuries: BCG in the treatment of superficial bladder cancer.从19世纪到21世纪：卡介苗在浅表性膀胱癌治疗中的应用
Eur Urol. 1992;21 Suppl 2:2-6. doi: 10.1159/000474913.
Zotero 插件